Axsome Therapeutics (AXSM) Operating Leases (2020 - 2026)

Axsome Therapeutics (AXSM) has 6 years of Operating Leases data on file, last reported at $22.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 6.36% year-over-year to $22.4 million; the trailing twelve-month figure through Mar 2026 stood at $22.4 million (down 6.36% YoY), and the FY2025 full-year result was $23.2 million, up 283.43% from the prior year.
• Operating Leases fell to $22.4 million in Q1 2026, from $23.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $23.9 million in Q1 2025 to a low of $6.0 million in Q4 2024.
• A 4-year average of $13.7 million and a median of $7.6 million in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases declined 16.27% in 2024 and soared 283.43% in 2025, its largest moves.
• Tracing AXSM's Operating Leases over 4 years: stood at $7.0 million in 2023, then decreased by 14.06% to $6.0 million in 2024, then soared by 283.43% to $23.2 million in 2025, then slipped by 3.44% to $22.4 million in 2026.
• Business Quant data shows AXSM's Operating Leases at $22.4 million in Q1 2026, $23.2 million in Q4 2025, and $23.0 million in Q3 2025.